English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Holotropic Breathwork Explained: A Psychedelic Journey Without the Plant Medicine
The first time I watched someone come out of a holotropic breathwork session, I genuinely thought they'd taken something. They were laughing, then crying, then quiet — eyes wet, face soft, like someone who'd just walked back from a long conversation with themselves. No ayahuasca. No mushrooms. Just two hours of fast, rhythmic breathing on a mat with a blanket and an eye mask. That's the strange promise of psychedelic breathing. You can access altered states — sometimes startlingly deep ones — using nothing but your own lungs. For people circling the idea of a plant medicine retreat but not quite ready (or not medically cleared) to drink ayahuasca or eat psilocybin, breathwork sits in a fascinating middle space. It's legal everywhere. It's relatively cheap. And it can, occasionally, knock you sideways in ways that genuinely resemble a psychedelic experience. Let's get into what it actually is, what it feels like, who shouldn't do it, and how honest people in this world talk about its limits. Holotropic breathwork was developed in the late 1960s by Stanislav Grof, a Czech psychiatrist who'd spent years studying LSD-assisted therapy. When LSD was made illegal, Grof — together with his wife Christina — went looking for a way to reach the same therapeutic states without the drug. They landed on breath. Specifically, sustained, deep, rapid breathing combined with evocative music in a held, supportive setting. The word holotropic means something close to “moving toward wholeness.” The premise is that your psyche, given the right conditions, knows how to surface what needs healing. The breath is the accelerator. The facilitator and the setting are the safety rails. It's worth saying: holotropic breathwork is one of several styles you'll encounter. There's also rebirthing breathwork (Leonard Orr, 1970s), Clarity Breathwork, Integrative Breathwork, Vivation, and a small fleet of newer trademarked methods. They differ in pace, theory, and how much weight they place on early childhood material. Holotropic is the one most explicitly aimed at producing psychedelic-style experiences. People want to know this, and most articles dodge it. So here's the honest version, drawn from sitting in a few sessions myself and talking with facilitators who've held hundreds. The first ten or fifteen minutes feel like work. You're breathing faster and deeper than you normally would — not panting, but a continuous, connected pattern with no pause between the inhale and the exhale. It's uncomfortable. Your hands might tingle. Your jaw might tighten. Some people get cramping in the fingers (it's called tetany, it's caused by the shift in blood chemistry, and it passes). Then somewhere between minute twenty and minute forty, something shifts. The breath starts breathing itself. Imagery shows up. Sometimes it's specific — a memory, a face, a place you haven't thought about in years. Sometimes it's abstract — colors, geometry, a sense of being very small or very large. Sometimes the body takes over and you're shaking, sobbing, or laughing without any narrative attached to it at all. A session typically runs two to three hours. Compared to an ayahuasca ceremony (six to eight hours, often with physical purging) or a psilocybin journey (four to six hours), it's a relatively contained experience. But the depth can surprise you. I've heard people describe breathwork sessions that hit harder than their first mushroom trip. Practitioners and participants describe a fairly consistent menu of effects. Take the longer list with a grain of salt — the research is still thin — but these are what come up over and over: A handful of small studies back parts of this up. Sarah Holmes's 1996 work suggested holotropic breathwork combined with psychotherapy reduced death anxiety and lifted self-esteem more than therapy alone. A 2015 study reported gains in self-awareness and what researchers described as positive character shifts — less reactivity, more patience. None of this is the same as a Phase 3 trial for psilocybin. But it's not nothing, either. This is the part of the conversation that often gets glossed over, and it shouldn't be. Holotropic breathwork is a controlled, voluntary form of hyperventilation. You're deliberately lowering the carbon dioxide in your blood for an extended period. For healthy people, this is generally low risk. For some people, it's genuinely dangerous. Reputable facilitators screen for the following before letting you in the room: If a retreat or facilitator doesn't ask you any health questions before signing you up, that's a red flag. The breathing itself is free; the safety comes from who's holding the space and whether they actually know what they're doing. If you're reading this, there's a decent chance you're weighing breathwork against a plant medicine retreat. They overlap in interesting ways, but they're not interchangeable. Here's how I'd lay out the trade-offs. It's legal. It's faster. It's cheaper — a weekend breathwork workshop can cost a few hundred dollars versus several thousand for a week-long ayahuasca retreat in Peru. The experience is more controllable; if it gets intense, you can slow your breath and bring yourself back. There's no purging. There's no two-day comedown. And you can practice (a milder version) on your own, between sessions, without involving anyone else. The evidence base for psilocybin and ayahuasca, particularly for depression, addiction, and end-of-life distress, is genuinely stronger at this point. The experiences tend to be longer, deeper, and more reliably mystical at full doses — which seems to matter for the kind of lasting reorganization people are after. Ayahuasca brings a centuries-old indigenous framework and the company of master plants, which is a different proposition than a Western therapeutic breathwork session. And honestly, for trauma that's locked very deep, some people only get there with the help of a substance. Many of the most thoughtful people in this space don't treat it as a versus question. They use breathwork as a regular practice and reserve plant medicine for less frequent, more intentional journeys. The two reinforce each other. Breathwork keeps you familiar with your own altered states, which makes a ceremony less disorienting when you do choose to sit. If you're new to this, don't start by Googling “holotropic breathwork technique” and trying it alone in your bedroom. The whole point of the method is the container — a trained facilitator, a partner to keep an eye on you, music chosen to support the arc of the session, and a group to integrate with afterward. A few practical pointers: Whether you ultimately drift toward breathwork, plant medicine, or some combination of both, the underlying skill is the same: getting comfortable with your own interior, learning to stay present when things get strange, and finding people who know how to hold the room. For readers wanting to take this further, a curated selection of breathwork and plant-medicine retreats can be browsed on our marketplace here. Start where you are. Breath is free, available, and surprisingly capable of taking you somewhere worth going.
Psilocybin for Treatment-Resistant Depression: What the Phase 2 Trial Really Showed
A few years back, a midstage clinical trial quietly shifted the conversation around psilocybin and depression. Not because it produced a miracle. Because it produced something more useful: real numbers, real risks, and a real signal that a single dose of a psychedelic — paired with therapy — can move the needle for people who've tried everything else. If you've landed here, you're probably not researching this out of casual curiosity. You're weighing whether plant medicine or a psychedelic-assisted retreat might help with depression that hasn't budged through SSRIs, talk therapy, maybe a stint of CBT, maybe years of feeling like you're shouting into a tunnel. So let's walk through what that trial actually found, what it didn't, and what it means for someone considering this path today. The trial, run by Compass Pathways, looked at a synthetic version of psilocybin — the active compound in magic mushrooms — given as a single dose alongside psychological support. The target population was people with treatment-resistant depression, meaning depression that hadn't responded to at least two prior treatments. This is the hardest end of the spectrum. These are the patients clinicians often feel stuck on. Two hundred and thirty-three participants across ten countries in North America and Europe were split into three dose groups: 25 mg, 10 mg, and 1 mg. That 1 mg group functioned as a low-dose comparator — basically a placebo with a faint shimmer. Patients received the dose in a supervised session with trained therapists present, then were followed for twelve weeks and assessed using a standard psychiatric depression scale. The big questions the researchers wanted answered were pretty practical ones. What's the smallest dose that actually does anything? How long does the benefit from a single dose last? And how safe is this when you give it to people who, almost by definition, are dealing with serious mental-health vulnerability? At the three-week mark, roughly a quarter of patients in the 25 mg group hit response criteria — meaningful symptom reduction on the depression scale. At twelve weeks, about one in five were still showing notable improvement. The 1 mg group landed at roughly half that rate. So the high dose roughly doubled the response compared to the comparator. One detail that caught analysts' attention: the response wasn't gradual. Some patients showed rapid symptom reduction by around week six. For anyone who's been on traditional antidepressants — which can take six to eight weeks just to start nudging anything — that's a different kind of timeline. A single supervised session, followed by weeks of sustained change, is not how SSRIs work. That said, let's keep our heads. A 20% response rate at twelve weeks is meaningful for a treatment-resistant population, but it also means roughly four out of five participants in the high-dose group did not maintain that response. This isn't a cure. It's a tool — possibly a powerful one — that helps a real but limited subset of people, at least with a single dose. Here's where the conversation gets honest. Over 90% of reported adverse effects were mild to moderate — headaches, nausea, the kind of stuff anyone who's read a ceremony account would expect. Twenty-four participants withdrew during the trial. And twelve reported severe effects including suicidal ideation, intentional self-injury, or suicidal behavior. The company noted that these severe events are unfortunately common in the treatment-resistant depression population to begin with — these are people already at elevated risk. That framing is medically accurate. It's also not a reason to wave the concern away. Psychedelics can crack things open. For someone whose internal landscape is already fragile, that opening needs serious infrastructure: skilled therapists, real screening, genuine aftercare, and an honest conversation about who shouldn't do this at all. One Wall Street analyst put it bluntly — the market response showed that investors hadn't fully appreciated the complexity of side effects in psychedelic medicine. Translation: people get excited about the upside and underestimate the work it takes to do this safely. That's worth remembering whether you're looking at a regulated clinical pathway or a retreat in the jungle. You might be wondering why a clinical trial matters if you're researching ayahuasca, psilocybin retreats, or other plant medicines outside the pharmaceutical pipeline. Here's the link: the trial validates something the indigenous and underground communities have said for decades — that these compounds, taken in a held, supported container, can produce durable shifts in depression. The clinical setting strips away ceremony and ritual, but the active ingredient and the basic logic — psychedelic plus skilled human support — is recognizably the same. What clinical trials can't tell you is what a five-day ayahuasca retreat in Peru with a curandero from a Shipibo lineage feels like. Or what it's like to sit with psilocybin truffles in the Netherlands with a facilitator who's guided five hundred sessions. Those experiences are different in ways research isn't designed to measure — and arguably can't. The clinical data should make you a more informed consumer of the retreat space, not less of one. If you're going to spend three thousand dollars and a week of your life on a ceremony, you want to know that the substance you're working with has real, studied effects on depression — and real, studied risks. Now you do. If this research nudges you toward exploring a retreat or a clinical program, here are the things to actually look into before handing over a deposit: The trial's response rate — meaningful but partial — is a useful reality check. A reputable facilitator should give you the same honest framing. Anyone selling certainty is selling something else. Phase 3 trials for psilocybin in depression have moved forward in the years since this initial midstage data, and regulators in North America and Europe continue to evaluate whether — and how — psychedelic-assisted therapy can be approved as a mainstream treatment. Parallel work continues on MDMA for PTSD, ibogaine for opioid addiction, and psilocybin for everything from end-of-life anxiety to alcohol use disorder. The clinical and traditional worlds are converging more than either side likes to admit. Researchers are starting to take the ceremonial container seriously. Retreats are starting to take screening and integration seriously. Somewhere in the middle, a more honest model of psychedelic healing is emerging — one that respects both the science and the centuries of indigenous knowledge that got us here. If depression has been the long backdrop of your life, and you've started to wonder whether plant medicine might offer something the prescription pad hasn't, that's a legitimate question to sit with. Read widely. Talk to people who've actually done this. Be honest about your own risk factors. For readers who want to take this further, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here — a useful starting point for seeing what the landscape actually looks like beyond the headlines.
Legal Psilocybin in Oregon: What a Real Mushroom Session Actually Looks Like
Oregon did something genuinely strange a few years back. It became the first U.S. state to build an actual legal framework for taking psilocybin mushrooms — not decriminalization, not a research loophole, but a licensed, supervised program where adults can sit with a facilitator and have a psychedelic experience without breaking the law. That program is now up and running, and if you've been quietly curious about it, you probably have questions. A lot of them. I've spent years in and around psychedelic and plant medicine circles — Peruvian ayahuasca lodges, Dutch truffle retreats, the gray-market underground here in the States — and the Oregon model is its own animal. It isn't a ceremony in the traditional sense. It isn't a clinical trial either. It's something new, and the rules around it shape the experience in ways most blog posts gloss over. So let's get into what actually happens, what it costs, and what you should think about before booking a session. The short version: Oregon voters passed Measure 109 back in 2020, which created a state-licensed system for what the law calls “psilocybin services.” It took a few years of rulemaking, but licenses have been issued, service centers are operating, and anyone 21 or older — Oregon resident or not — can legally book a session. You don't need a diagnosis. You don't need a doctor's referral. You do need to show up sober, sign paperwork, and do the whole thing at a licensed location. This is the part that trips people up: you cannot buy mushrooms and take them home. There's no dispensary model here. The psilocybin stays at the service center, and you take it under the supervision of a trained facilitator who stays with you for the entire experience. If you were hoping for the California weed-shop vibe, this isn't it. It's closer to going to an unusual kind of clinic — one with cushions, soft lighting, and an eight-hour appointment window. Only one mushroom species is permitted in the program: Psilocybe cubensis, the most commonly cultivated variety. The product can be combined with simple foods (a bit of chocolate, a tea), but it can't be mixed with alcohol, cannabis, or random homemade ingredients that might mess with how it hits. Every legal psilocybin experience in Oregon has three parts. The shape of it borrows heavily from how clinical psychedelic trials have been structured for the past two decades, which is itself borrowed from older indigenous ceremonial frameworks. The names are different. The bones are similar. Dosing usually lands somewhere between 20 and 30 milligrams of psilocybin, which is a solid full-immersion dose. You can ask for less. You can also request a “subperceptual” dose — the microdosing range — though most people booking a full session aren't there for that. The facilitator can offer what the rules call “supportive touch” — a hand on your shoulder, holding your hand — but only with explicit consent established beforehand. If you don't want to be touched, you say so during prep, and that's the end of it. This is where people get sticker shock. Oregon's program doesn't cap prices, so what you pay depends entirely on who you book with. The range right now runs from about $1,500 on the low end to north of $7,000 for premium multi-day retreat formats. The lower-cost end — roughly $1,500 to $2,500 — typically gets you one preparation session, one dosing session with a single facilitator, and one integration session. Nonprofit-leaning providers and smaller operators tend to cluster here. Some are actively trying to make access more equitable, especially for people from communities that have historically been shut out of legal psychedelics. The mid and high end — $4,000 to $7,500+ — usually means a more retreat-style experience: multiple days on site, two facilitators in the room, fancier accommodations, longer integration packages, sometimes group sessions with several participants. Some of the operators in this tier ran psilocybin truffle retreats in the Netherlands for years before Oregon opened, and they're essentially porting that model over. Is the expensive version “better”? Not necessarily. What you're paying for at the high end is comfort, polish, and more facilitator hours. What matters most for outcomes — the quality of the facilitator, the safety of the setting, the depth of integration — can absolutely be present at the lower price point. It's worth shopping around and asking blunt questions. Legal doesn't automatically mean good. The Oregon program is new, facilitators have varying backgrounds, and the screening you do as a consumer matters. A few things worth asking any provider before you hand over a deposit: If a provider gets defensive or vague when you ask these questions, that's data. The good ones welcome them. Here's the truth that gets buried under all the talk about doses and trip durations: the mushroom session itself is the easy part. The hard, slow, valuable work is what happens in the weeks and months after. People go into a psilocybin session hoping for a breakthrough — about their drinking, their depression, a relationship that's been stuck for a decade, grief they never quite processed. Sometimes that breakthrough shows up. More often, what shows up is raw material. Images, memories, feelings, a strange new clarity about something you'd been avoiding. None of that automatically translates into a changed life. You have to do something with it. The required integration session is a starting point, not a finish line. A lot of facilitators will recommend ongoing work with a therapist who understands psychedelic experiences, a peer integration group, journaling practices, or somatic work depending on what came up. If you're considering a session because you're struggling with addiction or trauma specifically, line up that ongoing support before you sit down — not after. The window for change is real, but it's not infinite. Legal psilocybin is a remarkable thing to have available, and for some people it can be genuinely life-shifting. It's also not for everyone, and the marketing around psychedelics tends to overshoot that point. If you have a personal or family history of psychotic disorders, this probably isn't your medicine. If you're on SSRIs and not willing or able to taper safely, the experience may be blunted or complicated. If you're in acute crisis — actively suicidal, in the middle of a mental health emergency — a psilocybin session is not a substitute for stabilization. And if you're going in expecting a tidy solution to messy problems, the mushrooms will, with great affection, hand you something else entirely. Plenty of people also find their healing through other paths — ayahuasca ceremonies with experienced curanderos, ibogaine for opioid dependency, ketamine-assisted therapy, or non-psychedelic approaches like somatic therapy and long-term meditation practice. The right tool depends on what you're working with. Psilocybin in Oregon is one option in a much wider landscape of plant medicine and psychedelic healing. If you're weighing this decision seriously, take your time. Talk to people who've done it. Read past the marketing copy. And if a more immersive retreat format calls to you — whether that's psilocybin in Oregon or something further afield — a range of vetted psychedelic retreats can be browsed on our marketplace here. Whatever you choose, choose it with your eyes open. That's most of the work right there.
Are Magic Mushrooms Actually Safe? What the Research Really Shows
Ask someone who has taken psilocybin mushrooms to describe what it felt like, and you tend to get answers that sound borrowed from a fever dream. They heard a color. They watched a sound walk across the room. The thud of a closing door arrived as a dark, jagged shape hanging in the air. None of that, on the face of it, sounds like a particularly safe afternoon. And yet — bear with me — magic mushrooms keep showing up in the data as one of the least physically dangerous psychedelics people use recreationally. A growing pile of survey data and clinical research suggests that psilocybin, the active compound in those mushrooms, has a remarkably gentle safety profile compared to almost anything else in the recreational drug conversation. For anyone weighing whether to attend a psilocybin retreat — or trying to make sense of the wider world of psychedelics, ayahuasca, and master plants — that's worth understanding properly. The Global Drug Survey, run by an independent British research outfit, has been collecting self-reported data from drug users around the world for years. In one widely-cited round, of more than 10,000 people who said they'd taken magic mushrooms in the prior year, only about 0.2% reported needing emergency medical treatment afterward. That number is less than a fifth of the rate reported by users of alcohol, cocaine, or methamphetamine in the same survey. That's striking. But before anyone treats it as gospel, a caveat: this is a survey, not a controlled clinical trial. People are answering questions about their own behavior, sometimes years after the fact, sometimes while still a bit nervous about admitting they ever took anything. There are no control groups. Memories distort. So the headline number is suggestive, not definitive — a useful data point, not the final word. Still, the pattern holds across multiple surveys and across decades of medical literature. Psilocybin has not been credibly linked to a single overdose death. Tens of millions of people have used it. The neuropharmacologist David Nutt at Imperial College London has been blunt about this: as far as anyone knows, no one has died from the drug itself. There's a particular reason researchers tend to put psilocybin in a different bucket from substances like alcohol or opioids. The experience is too disruptive — too cognitively demanding — to drive compulsive repeat use the way alcohol or stimulants do. You don't really come down from a strong mushroom trip thinking, can't wait to do that again tomorrow night. Most people need a few weeks. Sometimes a few months. Sometimes a year. Sometimes never. Pharmacologically, the brain also develops a sharp short-term tolerance to psilocybin. Take the same dose two days in a row and the second dose barely lands. That tolerance fades over about a week, but it makes daily-use patterns nearly impossible. The drug, in a sense, gets in its own way. This is part of why psilocybin keeps appearing in addiction research — not as an addictive substance, but as a potential tool for treating addictions to other things. Tobacco. Alcohol. Cocaine. Several small clinical trials have shown long-lasting reductions in substance use after just one or two guided psilocybin sessions, often paired with talk therapy. That's a remarkable thing for a so-called drug to do. Safe, in this context, doesn't mean risk-free. It means the risks are different from what most people assume. Here's what actually matters: None of these are reasons to dismiss psilocybin out of hand. They are reasons to take the decision seriously and to choose your context with care. The reason mushrooms keep showing up in mainstream science coverage isn't just the safety data — it's what's happening in the clinic. Trials at Johns Hopkins, NYU, Imperial College London, and a growing list of other institutions have produced striking results for treatment-resistant depression, end-of-life anxiety in people facing terminal illness, alcohol use disorder, and obsessive-compulsive symptoms. The mechanism isn't fully understood, but the working theory is something like this: psilocybin temporarily loosens the brain's habitual patterns. Networks that have been running the same depressive loop for years go quiet for a few hours. New connections form. The experience itself — often emotionally intense, sometimes mystical, sometimes deeply uncomfortable — seems to do most of the therapeutic work, with the neurochemistry as the doorway. Nutt and others have predicted that psilocybin will be approved as a prescription treatment for depression within the next handful of years. Regulatory progress has been slower than the early optimists hoped, but the direction is clear. What was a fringe research interest twenty years ago is now an active corner of psychiatric medicine. For a lot of readers, the question isn't really is this drug safe in the abstract. It's am I going to be safe if I do this. Different question. The honest answer depends almost entirely on dose, setting, and the people around you. A few things worth weighing before you book anything: Magic mushrooms aren't a magic answer. They're a tool, and like any tool, the results depend heavily on the skill of whoever's holding it — including you. The safety data is genuinely reassuring, but a number on a survey doesn't replace careful preparation, honest self-assessment, and good company. If something in this piece has nudged your curiosity past the abstract, a range of vetted psilocybin retreats can be browsed on our marketplace here. Take your time with the decision. The mushrooms, such as they are, aren't going anywhere.
Compass Pathways and the Rise of Corporate Psilocybin: What It Means for Retreat-Seekers
Here's a story that explains a lot about where psychedelic medicine is heading. A mother, a physician, watches her son collapse under the weight of OCD and depression. She reads everything. One night she stumbles on a small 2006 study suggesting psilocybin — the compound in magic mushrooms — might quiet the obsessive loops that conventional medicine couldn't touch. She finds an underground guide. Her son drinks the tea. Six hours later, something shifts. He goes back to school. He gets his life back. That family went on to launch a company now worth roughly $400 million, listed on the Nasdaq, running one of the largest psilocybin trials in history. For anyone researching ayahuasca, psilocybin, or other plant medicines as a way out of addiction, depression, or trauma, the rise of Compass Pathways is worth understanding. It's reshaping the whole landscape — including the retreat world you're probably reading about right now. The origin story matters because it explains the tension. Ekaterina Malievskaia and George Goldsmith weren't pharmaceutical executives. They were parents. After watching their son emerge from a single supervised psilocybin session looking like himself again — sleeping, exercising, returning to class — they did what desperate, well-resourced parents do. They threw money at the problem. Hundreds of thousands of dollars into psychedelic nonprofits. A small project on the Isle of Man offering psilocybin to hospice patients. A nonprofit called C.O.M.P.A.S.S. to bring these treatments to people who'd run out of options. Then, in 2016, they pivoted. The nonprofit shut down. A for-profit corporation launched in London. The reasoning, as they tell it: you cannot move a drug through regulatory approval on donations alone. The price tag for late-stage trials runs into the hundreds of millions. To reach the people who needed psilocybin most — the ones whose insurance might one day cover it — they needed venture capital, not philanthropy. That pivot didn't sit well with everyone. Several researchers and longtime advocates who'd helped them in their nonprofit days felt blindsided. Some still do. The argument that follows them around — that you can't ethically commercialize a sacrament — is one the company has spent years answering. By 2017, three names had quietly placed bets on Compass: Christian Angermayer (a German entrepreneur who'd had his own psilocybin experience and become an evangelist), Michael Novogratz (the crypto investor), and Peter Thiel (the PayPal cofounder). Each put in roughly a million pounds. Novogratz's framing was almost charmingly blunt — he'd taken a flyer on cryptocurrencies and made a fortune, so why not a flyer on something equally fringe? The money kept coming. A £25 million round in 2018. An $80 million Series B in 2019, then a record for the sector. A Nasdaq IPO in 2020 at a billion-dollar valuation. The company is now running a Phase 3 trial with nearly a thousand participants, testing a synthetic form of psilocybin (they call it COMP360) against treatment-resistant depression — the cases where SSRIs, talk therapy, and everything else have already failed. Analysts have floated peak sales numbers somewhere between $1.1 billion and $8 billion if the drug clears approval and gets expanded for other mental-health conditions. The first approvals could land as early as 2026. That's not a footnote. That's the medical mainstream walking into a room it's been locked out of since the 1960s. You might be wondering why a story about a publicly traded pharmaceutical company matters if you're researching, say, an ayahuasca retreat in Peru or a psilocybin ceremony in Jamaica. Fair question. Here's the honest answer: the two worlds are bleeding into each other, and the choices you make as a retreat-seeker are going to be shaped by what happens in those clinical trials over the next two years. A few things are likely to shift: This is the question I get asked most often by people deciding whether to book. The answer isn't binary, and anyone who tells you it is — on either side — is selling something. Plant medicine, when it works, doesn't work because the molecule is magic. It works because the molecule cracks something open, and what you do with the opening matters more than the opening itself. The single session that turned Allan Malievsky's life around wasn't just six hours of psilocybin. It was a darkened room, a trusted guide, music chosen with care, and — crucially — a family ready to support whatever came next. The medicine was the catalyst. The container was the cure. This is why master plants — ayahuasca, peyote, San Pedro, iboga, the whole lineage — have always been used inside ritual frameworks. The Shipibo curanderos in the Peruvian Amazon haven't been running clinical trials, but they have been refining a practice over generations. There's wisdom there that no Phase 3 protocol can replicate. There's also, let's be honest, plenty of charlatanism out there too. Both things are true. If you're weighing a retreat, a few honest filters worth running: Compass has earned its share of critics, and the criticism is worth understanding before you form an opinion. Some of it centers on patent applications that activists argued were overreaching — attempts, they said, to lock down techniques that the broader community considered shared heritage. Some of it is more philosophical: the discomfort with anyone profiting from substances that Indigenous communities have stewarded for centuries without commercial interest. You can think both things at the same time. You can be glad that millions of people with treatment-resistant depression may soon have a real option, and uneasy about the consolidation of plant medicine into corporate IP portfolios. The retreat world tends to live closer to the older, communal model. The clinical world is heading somewhere very different. Where you land on that spectrum will shape what kind of healing path makes sense for you. Read more than the marketing. Talk to people who've actually sat in ceremony — not the ones writing breathless trip reports, but the ones who can tell you what their life looked like six months later. Pay attention to whether they sound like they're still chasing the experience or whether they've integrated it and moved on. The second group is who you want to learn from. And give yourself permission to wait. The clinical trials will keep running. The retreats will still be there next year. If you're in acute crisis, that's a different conversation — find a clinician, find support, don't make a major decision while drowning. But if you're in the careful research phase, careful is good. This is real medicine, and real medicine deserves real preparation. If something here resonates and you want to see what's actually available, a range of curated ayahuasca and psilocybin retreats can be browsed on our marketplace here. Take your time. The right container matters as much as the medicine itself.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Celebrities and Psilocybin: What Famous Mushroom Trips Reveal About Plant Medicine
Something shifted in the public conversation around psilocybin somewhere around 2020. What used to be whispered about at house parties started showing up in late-night talk show segments, memoirs, and serious clinical trials. And famous people — the ones whose every habit gets dissected — started talking openly about their mushroom trips. Some of those stories are funny. Some are harrowing. A few hint at why psychedelics are finally being studied as serious tools for healing addiction, depression, and trauma. If you're reading this because you're quietly weighing whether a psilocybin retreat or another plant-medicine experience might be right for you, the celebrity anecdotes are worth paying attention to — not because famous people are reliable guides, but because their stories cover the full range of what can happen. The deep healing. The accidental tongue-biting. The ego death. The bad trip in an airport. All of it. Here's what some well-known names have shared, and what their experiences quietly tell us about the broader landscape of psychedelics, master plants, and the growing case for psychedelic-assisted recovery. Of all the celebrity psilocybin stories, Tyson's might be the most consequential. The former heavyweight champion has spoken publicly about being nearly suicidal at one point — masking a brutal depression behind the public bravado. He credits psychedelic mushrooms with pulling him back from that edge. He's since described psilocybin as “amazing medicine” and expanded his exploration into other compounds, including DMT and the venom of the Bufo alvarius toad (often called 5-MeO-DMT). His framing matters. He doesn't call it a party drug. He calls it medicine. That language shift — from recreation to healing — is exactly what's driving the current research surge around psychedelic therapy. For readers thinking specifically about plant medicine for addiction, Tyson's arc is worth sitting with. He's been candid about substance abuse earlier in his life. The fact that he found something genuinely useful in psilocybin lines up with what early clinical trials at Johns Hopkins and NYU are now finding: psychedelics, used in the right setting, can interrupt the patterns that keep addiction locked in. Bell's entry point will sound familiar to a lot of you. She read Michael Pollan's How to Change Your Mind, got curious, and decided to try psilocybin for her birthday — with her husband acting as a sober trip-sitter. She had been managing depression and anxiety with medication for years. Her takeaway: there are places in your own mind that ordinary therapy can't quite reach, and certain compounds can open the door. That's not a clinical claim — it's a personal one — but it tracks with what researchers studying psilocybin for treatment-resistant depression are reporting. The drug seems to loosen rigid thought patterns long enough for someone to see themselves from a new angle. What's instructive about her story isn't the trip itself. It's the preparation. She didn't grab mushrooms at a festival. She researched, chose a safe environment, and had a trusted person present. Those three things — intention, set, and setting — are the foundation of every reputable psychedelic retreat in operation today. You'll hear the term “master plants” thrown around in retreat brochures and Instagram posts. It refers to a specific category of plants used in Amazonian and Andean traditions for teaching, healing, and visionary work. Ayahuasca is the most famous one. San Pedro and peyote are others. Tobacco — in its raw, sacred form, not cigarettes — is considered a master plant in many lineages. Psilocybin mushrooms aren't strictly classified as “master plants” in the traditional Amazonian sense, but they belong to the same broad family of substances that indigenous and contemporary practitioners treat with deep ceremonial respect. The shared idea is that these aren't drugs you take. They're something more like teachers you sit with. That distinction matters when you're choosing a retreat. A serious facilitator talks about the medicine as a relationship — preparation, ceremony, integration. A sketchy one talks about it as a product. If you're reading promotional copy and it sounds more like a spa weekend than a sacred container, that's a signal. Harry Styles bit off the tip of his tongue. Seth Rogen accidentally ended up in Paris. Nick Kroll let his friends bury him in 50 pounds of sea kelp. Miley Cyrus had a full anxiety attack at an airport. Frances McDormand had her experimental phase. These stories are funny in the retelling because everyone survived intact, more or less. But strip away the celebrity gloss and you see the same pattern that lands ordinary people in genuine trouble: no preparation, no setting, no sitter, no plan. The mushrooms were treated as recreation, not as anything that required respect. Sometimes you get a fun story. Sometimes you get a panic attack you carry for months. Here's what an honest read of the funny stories tells you: None of this is to scold anyone. It's to point out that the same compound that helped Tyson step back from suicide also sent a 17-year-old into a panic spiral in an airport terminal. The molecule isn't the whole story. The container is. A legitimate psilocybin retreat — and there are a growing number of legal ones, particularly in Jamaica, the Netherlands, and now Oregon — exists precisely to provide what those celebrity party stories lacked. Structure. Screening. Trained facilitators. A physical space designed for safety. And, critically, integration support afterward. Here's roughly what to expect from a reputable program: The integration piece is the part most people underestimate. The trip is dramatic. The integration is where the actual rewiring happens. Skip it and you risk having a fascinating weekend that fades back into the same old patterns within a month. This question comes up constantly, and the answer keeps changing. As of now, Oregon is the only U.S. state with a regulated psilocybin services program — adults can access it through licensed facilitators. Colorado is rolling out a similar framework. Several cities, including Denver, Oakland, Santa Cruz, and Washington D.C., have decriminalized possession of psilocybin to varying degrees, which is not the same as legalization. Outside the U.S., Jamaica has long been a destination because psilocybin was never criminalized there. The Netherlands permits sale of psilocybin-containing truffles, which are biologically similar to mushrooms. Several countries in Central and South America have ambiguous or tolerant legal frameworks around traditional use. The point isn't to memorize the map. It's to know that you don't have to break the law or trust a stranger at a festival to access this medicine in a serious setting. The infrastructure for safe, legal psychedelic experiences has grown enormously over the last few years. You might roll your eyes at celebrity drug stories — fair enough — but the cultural shift they represent is real. When Tyson talks about psilocybin saving his life, when Bell credits it with reaching depression her meds couldn't touch, when serious actors and athletes describe ego death without irony, the conversation moves. Stigma loosens. Research funding follows. Insurance companies start paying attention. Veterans' organizations start advocating. For someone considering a retreat — perhaps because conventional treatment for depression, addiction, or trauma hasn't done what you hoped — that cultural shift translates into something concrete: more options, more research, more legitimate places to go, and far less shame about going there. If the stories above sparked something in you, take it seriously but don't rush. Read more. Talk to people who've done it. Ask hard questions of any retreat you consider — about screening, facilitator training, medical support, and integration. For readers ready to look at specific options, a curated selection of psilocybin and broader plant-medicine retreats can be browsed on our marketplace here. The celebrities had their wild nights. The actual work — the kind that changes a life rather than producing a good talk-show anecdote — happens in much quieter rooms, with much more preparation, and with people who know what they're doing.
Ibogaine Visions and the Question of Reincarnation: What People Actually See
Somewhere around hour six, people start describing things they have no business knowing. A village they’ve never visited. A death they didn’t die. A face that feels more familiar than their own mother’s. Ibogaine does this. It’s one of the strangest features of an already strange medicine, and if you’re researching it seriously — maybe for an addiction, maybe for something heavier you can’t name — you’re going to run into the reincarnation reports sooner or later. So let’s talk about them honestly. Not as proof of anything cosmic, not as hallucinations to dismiss, but as a real thing that happens to real people in ibogaine ceremonies and clinics around the world. What the visions tend to look like. Why they hit so hard. And what to do with them once you’re back on your feet. Ibogaine is an alkaloid extracted from the root bark of the iboga shrub, used for generations in Bwiti spiritual practice in Gabon and now studied internationally for opioid and stimulant addiction. It’s not recreational. There’s no euphoria to chase. A full flood dose lays you flat for twelve to thirty-six hours and walks you through what practitioners often call a “waking dream state” — long, narrative, dense with autobiography. The first phase is usually visual. People describe a film reel: scenes from their childhood, half-forgotten arguments, the face of someone they hurt, the body they had at seven. The second phase shifts inward — quieter, more cognitive, more like sorting through a filing cabinet with the lights on. Somewhere in those phases, a subset of people report something else entirely. They report being someone else. You’ll find these stories on forums, in clinic testimonials, in the older Bwiti ethnographies, and in the quiet conversations after a ceremony when nobody’s recording anything. They share a strange consistency. Someone lies down a 41-year-old software engineer from Berlin and meets, for hours, a 19-year-old conscript in a war that ended generations ago. They feel the mud. They feel the fear. They feel the moment of dying. And then they wake up still themselves, still 41, but rearranged. Common features of these visions: Whether these are literal past lives, archetypal memories, ancestral echoes, or the brain doing something extraordinary with its own material — the honest answer is nobody knows. Ibogaine researchers tend to call them autobiographical or symbolic; Bwiti elders would call them visits with ancestors; the person who had the vision usually doesn’t care what we call them, because the experience itself is so vivid it bypasses the question. Ayahuasca gives you cosmic geometry and serpents. Psilocybin gives you ego dissolution and the feeling of being woven into everything. Ibogaine, more than any of them, gives you narrative. Long, coherent, autobiographical narrative. People describe it less as tripping and more as watching a documentary about themselves — or, sometimes, about someone they were before. A few theories on why: None of this proves reincarnation. It does suggest why ibogaine, of all the plant medicines, is the one most likely to drop you into someone else’s life for an evening. Here’s the part that matters if you’re actually considering iboga work. The reincarnation vision, whatever it is metaphysically, tends to do real work. People who arrive at a clinic to treat heroin addiction sometimes come out the other side talking about a life they lived in 1840 — and also, separately, find that the craving is gone. The two things aren’t necessarily related. But they aren’t unrelated either. What I’ve heard, again and again, is that the vision gave the person a frame for pain they couldn’t previously locate. A man who couldn’t explain his terror of water meets, on ibogaine, the body of someone who drowned. He doesn’t become a believer in past lives. He just finds, afterward, that he can swim. A woman with a self-destructive pattern she’d worked on for a decade sees, in vision, a life ended by violence she didn’t cause and couldn’t prevent. The pattern loosens. Whether that’s healing through symbol or healing through literal memory, the loosening is real. This is part of why ibogaine has earned its reputation in addiction recovery — not just for interrupting the neurochemistry of dependence, but for handing people a story large enough to hold what they’ve been running from. The plant medicine community sometimes calls these the “master plants” for exactly this reason. They teach. Iboga teaches in long, autobiographical paragraphs. If you have one of these experiences — or if you’re reading this because someone you love did — a few practical thoughts from people who’ve worked this territory: The worst outcomes I’ve seen aren’t from the visions themselves — they’re from people who either build an identity around being the reincarnation of someone famous (please don’t) or who shove the whole experience in a drawer because it doesn’t fit their worldview. Both lose the gift. Reincarnation visions sound romantic. The medicine that produces them is not. Ibogaine carries genuine cardiac risk and has been associated with fatalities, almost all linked to undiagnosed heart conditions, drug interactions, or unsupervised use. This is not a substance to take in a friend’s basement. A reputable ibogaine clinic will require an EKG, bloodwork, a full medication review, and medical monitoring throughout the session. If a provider isn’t asking about your heart, walk away. If you’re considering iboga for addiction recovery specifically, look for facilities with medical staff on site, transparent screening protocols, integration support after the experience, and honest communication about what ibogaine can and can’t do. It’s not a magic bullet. It’s a doorway, and what you do on the other side of it matters more than the doorway itself. For readers who want to take this further, a curated range of ibogaine and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide — whether the right next step is a clinic, more reading, or simply sitting with the question a while longer — give the decision the weight it deserves. Visions of past lives are not the strangest thing iboga will hand you. The strangest thing is how ordinary your current one starts to feel afterward, and how much of it suddenly seems worth showing up for.
Microdosing Psychedelics: An Honest Look at What the Research Actually Shows
A friend once told me she'd been microdosing psilocybin for six weeks and felt like the volume knob on her anxiety had been turned down by about a third. Not silenced. Just turned down. That's the kind of report you hear constantly in this corner of the psychedelic world — quiet, modest, hard to verify, and oddly compelling. Microdosing psychedelics has moved from Silicon Valley curiosity to mainstream conversation over the past few years, and the questions I get from readers researching plant medicine almost always include some version of: should I try this before committing to a full ceremony? Fair question. Let's get into what microdosing actually is, what the science says, and what it doesn't. A microdose is what researchers politely call a sub-perceptual dose — small enough that you don't feel high, don't see walls breathing, don't have any of the textbook psychedelic experiences. You can drive. You can answer emails. You can sit through a meeting without anyone suspecting a thing. That's kind of the whole point. Roughly speaking, a microdose lands somewhere between a tenth and a twentieth of a recreational dose. For the most common substances people use, that works out to: Finding your dose is genuinely a trial-and-error process. People who are sensitive to serotonergic compounds can feel noticeable effects at amounts that another person wouldn't register at all. The rule of thumb most experienced microdosers follow: if you can feel it, you took too much. A proper microdose should slide under your perception, not announce itself. The protocol most people reference comes from researcher James Fadiman, who suggested dosing once every three to four days for around ten weeks, then taking a break. The logic is partly about tolerance — psychedelics build it fast — and partly about not letting the practice become invisible background noise. Others run shorter cycles, or use a two-days-on, one-day-off rhythm. There's no single right answer, and frankly, anyone who tells you there is hasn't been paying attention. The reasons cluster into two broad camps. The first is mental health — people dealing with depression, anxiety, PTSD, ADHD, or OCD who either haven't responded well to conventional medication or don't love the side effects that come with it. The second is what you might call optimization — focus, creativity, energy, mood, the feeling of being a little more present and a little less stuck in your own head. The mental health angle is where things get interesting, and where I see the most readers genuinely curious. If you've been on SSRIs for a decade and you're tired of feeling emotionally flattened, the idea of a sub-perceptual dose of psilocybin twice a week sounds appealing. Journalist Erica Avery wrote publicly about microdosing LSD lifting her out of a depressive episode, and writer Ayelet Waldman built a whole book around her experience doing the same. Waldman's depression stayed gone after she stopped. Avery's came back — and she eventually concluded that occasional larger doses worked better for her than ongoing small ones. Which is the most honest thing anyone can say about this practice: your mileage will vary. Dramatically. Here's where I have to put on my skeptic hat, because the gap between what people report anecdotally and what controlled studies have found is bigger than the microdosing community generally admits. The obvious worry with any sub-perceptual practice is that the effects are mostly placebo. You believe the tiny dose will help, so it does. That's not nothing — placebo effects are real and clinically significant — but it matters for the question of whether the molecule itself is doing anything. A double-blind, placebo-controlled trial published in Biological Psychiatry in 2019 tried to answer this. Researchers gave healthy volunteers LSD at 6.5, 13, and 26 micrograms versus a placebo. They found dose-related effects on subjective experience — feelings of vigor went up, but so did anxiety. Creativity scores actually got worse on LSD. Cognitive performance didn't improve. None of which lines up neatly with the rosy reports you read online. One of the researchers noted that benefits might only show up after repeated dosing over time, which the study didn't measure. And the 26-microgram dose is arguably no longer a microdose at all — most harm-reduction guides classify it as a low recreational dose. So the picture is muddier than either side of the debate likes to admit. Fadiman ran a much larger observational study with over a thousand participants across 59 countries. People microdosing LSD or psilocybin roughly every three days reported improvements in mood, productivity, focus, energy, relationships, and health habits. Some had even tapered off antidepressants in favor of microdosing. Encouraging — but it's a self-report study with no control group. Fadiman himself was careful to note that people whose primary issue is anxiety probably shouldn't microdose, because some users find it amps anxiety up rather than down. That tracks with the controlled trial. A 2019 rodent study found that microdoses of DMT given over seven weeks improved measures of depression and anxiety without messing with cognition. Promising, but it's rats, not people, and the leap from rodent brain to human depression is famously treacherous. We don't have meaningful human data on microdosing DMT for mental health yet. A few things I think are worth saying plainly: This is probably the question that matters most for readers weighing a retreat. Microdosing and ceremonial plant medicine are different tools doing different jobs. A microdose is a quiet nudge to your nervous system, maybe useful for taking the edge off a difficult month or unsticking a creative block. A full ayahuasca ceremony, or a psilocybin retreat with experienced facilitators, is something else entirely — a full confrontation with whatever you've been carrying. People recovering from addiction, in particular, tend to find that microdosing alone doesn't get them where they need to go. The research on psychedelics and addiction recovery — the work on ibogaine for opioid dependence, psilocybin for alcohol use disorder, ayahuasca for trauma underlying substance use — involves full doses in carefully held settings, not sub-perceptual experiments at the kitchen table. That said, some people use microdosing as a gentle on-ramp. A way to develop a relationship with these compounds and notice how their own system responds before committing to a multi-day retreat. There's logic to that, as long as you're honest about what microdosing can and can't do. If you're chronically anxious, on psychiatric medication, or already suspect you're someone who reacts strongly to substances, the honest answer is probably no — or at least not without serious thought and ideally a clinician who knows what you're up to. If you're a generally stable person curious about what a slightly quieter mind might feel like, and you have access to reliable material, it might be worth a careful experiment. Start lower than the standard protocol. Keep a journal. Take real breaks. Pay attention to what changes and what doesn't. And if what you're really looking for is the deeper work — the kind that addresses trauma, addiction, or the persistent sense that something in your life is stuck — microdosing is unlikely to be the whole answer. For readers who want to explore the fuller path, a curated range of psychedelic and plant-medicine retreats can be browsed on our marketplace here. Whatever direction you go, go slowly. These compounds reward patience and humble the people who don't bring it.
Synthetic Psilocybin and the Pharma Race to Medicalize Magic Mushrooms
Somewhere right now, in a quiet clinical room in London or Toronto or San Diego, a person with depression that hasn't budged for years is swallowing a measured dose of laboratory-made psilocybin under the gaze of two trained therapists. No shaman. No icaros. No jungle. Just a sofa, an eye mask, a curated playlist, and a molecule that — chemically speaking — is identical to the one inside a Psilocybe cubensis mushroom growing in a damp Oaxacan field. This is the version of psychedelics that's about to go mainstream. And if you're researching an ayahuasca retreat, a psilocybin ceremony, or any kind of plant-medicine experience for help with depression, addiction, or trauma, it's worth understanding what's actually being built in the pharmaceutical lane — because it changes the landscape you're choosing from. Compass Pathways became the first psilocybin-focused company to trade publicly on a major US exchange, and its CEO has been refreshingly blunt about one thing: they don't grow mushrooms. They synthesize the active compound in a lab. The reasoning is practical, not philosophical. Regulators trust standardized batches. Doctors want precise dosing. A 25-milligram capsule made in a controlled facility is easier to study than a handful of dried caps that might vary in potency by a factor of three. The FDA granted the company breakthrough therapy designation back in 2018 for treatment-resistant depression — the term for depression that hasn't responded to at least two rounds of conventional antidepressants. That designation doesn't mean approval. It means the agency agrees the unmet need is serious enough to fast-track the review process. Phase II trials are now running across roughly nine countries, testing different dose strengths to find the sweet spot before Phase III. The internal target is to have a legally prescribable psilocybin therapy on the market within the next couple of years. Whether they hit that timeline or not, the direction is clear: psilocybin is moving from the Schedule I list toward the prescription pad, one trial at a time. Here's where it gets interesting for anyone weighing a retreat. The clinical-trial version of a psilocybin session looks almost nothing like an Amazonian ayahuasca ceremony or a Mazatec velada. There's no group circle. No master plants in the traditional sense. No fasting protocols rooted in centuries of indigenous practice. The set is medical. The setting is medical. The framing is medical. That's not a criticism — it's a description. The clinical model is built to satisfy regulators and insurance companies, and it's designed for people who can't or won't travel to Peru, Costa Rica, or the Netherlands. For someone with severe depression who's been failed by SSRIs, having a covered, supervised psilocybin session in their own city might be the most accessible option they ever get. But it's a different experience from what plant-medicine retreats offer, and it answers a different set of questions. A retreat invites you into a tradition, a community, sometimes a worldview. A clinical session offers you a molecule, a sofa, and a follow-up appointment. Both can be profoundly helpful. They aren't the same thing. I get asked this almost every month. Someone reads an article about MDMA for PTSD or psilocybin for depression, sees the phrase “by 2026 or 2027,” and wonders whether they should just hang on a couple more years. My honest answer: it depends on how acute your situation is, what you're trying to address, and what kind of experience you're actually drawn to. If you're functional but stuck — patterns you can't break, grief you can't process, addictions that keep pulling you back — waiting for a clinical model that may or may not arrive on schedule is a real cost. Years of your life are not a small thing. Plenty of people who've sat in well-run ceremonies describe shifts that conventional therapy hadn't touched in a decade. The catch: the quality of the container matters enormously, and bad retreats absolutely exist. If you're in crisis — actively suicidal, in the grip of a substance dependency that's life-threatening, or managing a serious psychiatric condition — a retreat is usually not the right first move. Ceremonies are intense. They can surface material faster than you have support to handle. A reputable retreat will screen you out if you're in that zone, and if they don't, that itself is a red flag. The plant-medicine world isn't regulated the way the pharma world is. That's both its gift and its danger. The good retreats take screening seriously, run small groups, have medical staff on hand, and put as much emphasis on integration as they do on the ceremony itself. The bad ones take your money, hand you a cup, and send you back to the airport with a head full of unprocessed material and no support. A few things I'd want to know before sending money to any retreat center: For people specifically considering plant medicine for addiction, ibogaine deserves a separate conversation — it's a different molecule with a different risk profile (including real cardiac risk) and requires medical supervision that goes beyond what most ayahuasca retreats provide. Don't lump it in with mushrooms or ayahuasca just because they all fall under the “psychedelic” umbrella. The Compass CEO used the phrase “Cambrian explosion” to describe what's coming in the broader psychedelic and mental-health space. He's probably right. We're going to see prescription psilocybin, MDMA-assisted therapy, ketamine clinics on every other block, decriminalization measures in more cities, indigenous-led retreats fighting to protect their traditions, venture-backed startups trying to patent everything that isn't nailed down, and a long tail of underground practitioners doing what they've been doing for fifty years. The reader who benefits most from all this won't be the one who picks a side. It'll be the one who understands the differences — between a ceremony and a clinical session, between a master plant and a synthesized molecule, between a tradition with thousands of years behind it and a startup with a Series B. Both lanes can serve real people. Neither is the answer for everyone. If you've read this far, you're probably not researching idly. You're weighing something specific. For readers who want to take this further, a range of curated psychedelic and plant-medicine retreats can be browsed on our marketplace here — useful for getting a sense of what's actually out there before you commit to anything. Take your time. The molecule will still be there next month, and so will the vine.
Cacao Ceremony: What It Really Is, How It Feels, and Why It Matters
The first time I drank ceremonial cacao, I was sitting on a damp log in a pine forest in Maine, full moon overhead, expecting something resembling hot chocolate. What landed in my wooden cup was darker, grittier, and considerably more bitter than anything I'd associated with the word “chocolate.” I sipped it anyway. An hour later, I understood I'd been drinking the wrong cacao my entire life. This isn't a story about a psychedelic blowout. Cacao isn't ayahuasca. It won't dissolve your ego or send you spiraling through fractal jungles. But for a lot of people moving through the broader world of plant medicine and psychedelic healing, cacao has become a kind of gentle on-ramp — a way to learn what it feels like to sit in ceremony, drop into the body, and meet a plant with respect before encountering something stronger. If you're researching retreats and you keep seeing cacao mentioned alongside ayahuasca, San Pedro, and psilocybin, here's what's actually going on. A cacao ceremony is a ritual gathering — usually in a circle, often around a fire or altar — where participants drink a strong dose of ceremonial-grade cacao prepared with intention. There's typically a facilitator or shaman holding the space. There may be songs, prayers, silence, breathwork, journaling, or movement. The specifics vary wildly depending on the lineage and the facilitator's training. The cacao itself is the centerpiece, and this is where most newcomers get tripped up. Ceremonial cacao is not the cocoa powder in your pantry. The cacao fruit is harvested in Central or South America, fermented to strip away the pulp, and the beans are ground whole into a thick paste. Nothing is removed. No fats stripped out, no alkaloids isolated, no sugar dumped in. It's the full, unaltered plant. The comparison I keep coming back to: store-bought cocoa is to ceremonial cacao what a fast-food orange juice pouch is to a freshly squeezed orange. Same family. Different universe. Cacao has been used ceremonially for thousands of years across what we now call Mexico, Guatemala, Belize, and Honduras. The Maya and Aztec civilizations treated it as sacred — a food for royalty and a medicine for ritual. It appeared in marriage ceremonies, in offerings to deities, in funerary rites. The word "cacao" itself traces back to Mesoamerican languages, and archaeological residue testing has found cacao traces in ceremonial vessels dating back over three millennia. The modern revival, mostly Western-led and concentrated around facilitators in Guatemala, Bali, Costa Rica, and the U.S. wellness scene, is a more recent phenomenon. Some of it honors the original traditions carefully. Some of it doesn't. As with any plant medicine making the leap from indigenous context to global retreat circuit, there's a wide spectrum of integrity out there. Worth knowing before you book. No. Not in the way ayahuasca, psilocybin, or ibogaine are psychedelic. You won't hallucinate. You won't lose your sense of self. You won't see geometric patterns or commune with entities from other dimensions. If that's what you're after, cacao isn't your medicine. What cacao does is more subtle, and that subtlety is exactly why some people dismiss it and others swear by it. The active compounds — theobromine, anandamide, phenylethylamine, magnesium, a small amount of caffeine — work together to gently elevate mood, increase blood flow, soften the nervous system, and open up emotional access. Theobromine is a vasodilator; you'll often feel warmth spreading through your chest within twenty or thirty minutes. Anandamide is sometimes called the “bliss molecule.” Phenylethylamine is associated with feelings of attraction and connection. Put that together in a ceremonial dose (usually 30 to 45 grams of pure cacao paste, far more than a chocolate bar) and you get a state that's hard to describe but easy to recognize once you've felt it: alert but not wired, soft but not sleepy, emotionally accessible without being overwhelmed. People cry. People laugh. People sit silently for two hours and report feeling fundamentally rearranged afterward. A lot of facilitators in the broader plant medicine world use cacao as a complementary practice. There are practical reasons for this: This is part of why cacao retreats and cacao ceremonies are increasingly stitched into broader plant medicine programming, especially in places like Guatemala's Lake Atitlán region, Costa Rica's Nicoya Peninsula, and parts of Bali. Every facilitator does this differently, but the rough arc tends to look something like this. You arrive, leave your shoes at the door, and find a cushion in the circle. There's usually an altar in the center — flowers, candles, sometimes crystals or feathers, sometimes nothing more than a single carved wooden bowl. The facilitator opens the space, sets intentions, may invoke directions or sing an opening song. Then the cacao is served, cup by cup, often with eye contact and a quiet exchange. You sit with your cup. You set your own intention — what you're sitting with, what you're asking for, what you want to release. You drink. The next two to four hours are loosely held. There might be guided meditation, ecstatic dance, sharing circles, breathwork, or extended silence. The facilitator's job is to hold the container, not to direct your experience. You go where the medicine takes you, which for cacao usually means somewhere quieter and more emotionally honest than your day-to-day mind. Cacao is broadly safe, but it isn't for everyone. A few honest caveats: The cacao world ranges from deeply traditional Maya-rooted ceremonies led by indigenous abuelas in Guatemala to weekend wellness pop-ups in converted yoga studios run by someone who took a five-day training. Both can be meaningful. Neither is automatically legitimate just because it's labeled “ceremony.” A few things to look for: For readers who want to take this further, a range of curated cacao and plant medicine retreats can be browsed on our marketplace here. Whether cacao becomes a standalone practice or a doorway into deeper psychedelic and plant medicine work, the value is the same: you learn what it feels like to actually sit with a plant, ask it something, and listen to what comes back.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
